IRIS

Aims to develop imaging biomarker signatures to predict prognosis and response to immunotherapy. By combining radiomics and artificial intelligence, this future start-up aims to transform the analysis of medical images into a powerful predictive tool, enabling greater personalisation of oncology treatments.